Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18120885 | 0.95 | NPC1 (0.57) | NPC1RAB9AKDM4EMAPK10HSD17B10 | |
| Trifluoroacetic Acid SCHEMBL18108697 | 0.86 | AURKA (0.56) | FLT3 | |
| SCHEMBL18108756 | 0.83 | MAPK1 (0.61) | MAPK10CDK7ROCK2CDC7DAPK3 | |
| Trifluoroacetic Acid SCHEMBL18108590 | 0.82 | CDK7 (0.44) | CDK7ROCK2CDC7DAPK3PRKD3 | |
| SCHEMBL8252025 | 0.82 | MAPK1 (0.60) | NPC1RAB9AKDM4EMAPK10HSD17B10 | |
| SCHEMBL18108624 | 0.79 | AURKA (0.58) | NPC1RAB9AKDM4EMAPK10HSD17B10 | |
| SCHEMBL18108646 | 0.79 | HDAC6 (0.52) | MAPK10CDK7ROCK2CDC7DAPK3 | |
| SCHEMBL18120892 | 0.79 | AURKA (0.59) | NPC1RAB9AFLT3 | |
| SCHEMBL18108595 | 0.78 | MAPK1 (0.60) | CDK7ROCK2CDC7DAPK3PRKD3 | |
| SCHEMBL18108645 | 0.78 | TTK (0.56) | RAB9AKDM4EHSD17B10CDK7ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-05-21 | — | — | US | claimed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | claimed |
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2019-05-21 | — | — | US | disclosed |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10294207-B2 | Pyrazole derivatives as TNIK, IKKϵ and TBK1 inhibitor and pharmaceutical composition comprising same | TNIK, TNNI3K, TNK1 | NPC1 2878/4885RAB9A 3308/4885KDM4E 2206/4885 |
| US-20160289196-A1 | PYRAZOLE DERIVATIVES AS TNIK, IKKe AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNNI3K, TNK1 | NPC1 2944/4885RAB9A 3052/4885KDM4E 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.